Skip Navigation


Journal of Intellectual Property Law & Practice Advance Access originally published online on June 12, 2008
Journal of Intellectual Property Law & Practice 2008 3(8):491-493; doi:10.1093/jiplp/jpn109
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
3/8/491    most recent
jpn109v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Inman, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press. All rights reserved

Current Intelligence

Biogen insufficiency: does it still have teeth?

Paul Inman
Howrey LLP, London

H. Lundbeck A/S v Generics (UK) Limited, Arrow Generics Limited, Teva UK Limited and Teva Pharmaceuticals Limited [2008] EWCA Civ 311 CA (Civ Div); Biogen Inc. v Medeva Plc [1997] RPC 1 HL

The Court of Appeal recently overturned a first instance decision of the Patents Court when it found Lundbeck's claims to its patented enantiomer product escitalopram valid and, in so doing, shed new light on the interpretation of the House of Lords' ruling in Biogen v Medeva on insufficiency.

Correspondence: Email: inmanp{at}howrey.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.